Precompetitive Consensus Building to Facilitate the Use of Digital Health Technologies to Support Parkinson Disease Drug Development through Regulatory Science
Open accessThe DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
Innovative tools are urgently needed to accelerate the evaluation and subsequent approval of novel treatments that may slow, halt, or reverse the relentless progression of Parkinson disease (PD). Therapies that intervene early in the disease continuum are a priority for the many candidates in the drug development pipeline. There is a paucity of sensitive and objective, yet clinically interpretable, measures that can capture meaningful aspects of the disease. This poses a major challenge for the development of new therapies and is compounded by the considerable heterogeneity in clinical manifestations across patients and the fluctuating nature of many signs and symptoms of PD. Digital health technologies (DHT), such as smartphone applications, wearable sensors, and digital diaries, have the potential to address many of these gaps by enabling the objective, remote, and frequent measurement of PD signs and symptoms in natural living environments. The current climate of the COVID-19 pandemic creates a heightened sense of urgency for effective implementation of such strategies. In order for these technologies to be adopted in drug development studies, a regulatory-aligned consensus on best practices in implementing appropriate technologies, including the collection, processing, and interpretation of digital sensor data, is required. A growing number of collaborative initiatives are being launched to identify effective ways to advance the use of DHT in PD clinical trials. The Critical Path for Parkinson’s Consortium of the Critical Path Institute is highlighted as a case example where stakeholders collectively engaged regulatory agencies on the effective use of DHT in PD clinical trials. Global regulatory agencies, including the US Food and Drug Administration and the European Medicines Agency, are encouraging the efficiencies of data-driven engagements through multistakeholder consortia. To this end, we review how the advancement of DHT can be most effectively achieved by aligning knowledge, expertise, and data sharing in ways that maximize efficiencies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Dorsey, E. R., Elbaz, A., Nichols, E., Abbasi, N., Abd-Allah, F., Abdelalim, A., Adsuar, J. C., Ansha, M. G., Brayne, C., Choi, J.-Y. J., et al. (2018) · The Lancet Neurology · doi:10.1016/s1474-4422(18)30295-3 · Cited by 2,816
Self-citationObeso, J. A., Stamelou, M., Goetz, C. G., Poewe, W., Lang, A. E., Weintraub, D., Burn, D., Halliday, G. M., Bezard, E., Przedborski, S., et al. (2017) · Movement Disorders · doi:10.1002/mds.27115 · Cited by 859
Self-citationTechnology in Parkinson’s disease: challenges and opportunities
Espay, A. J., Bonato, P., Nahab, F. B., Maetzler, W., Dean, J. M., Klucken, J., Eskofier, B. M., Merola, A., Horak, F., Lang, A. E., et al. (2016) · Movement Disorders · doi:10.1002/mds.26642 · Cited by 654
Self-citationSim, I. (2019) · New England Journal of Medicine · doi:10.1056/nejmra1806949 · Cited by 491
Real-world evidence and real-world data for evaluating drug safety and effectiveness.
Corrigan-Curay, J., Sacks, L., & Woodcock, J. (2018) · JAMA · doi:10.1001/jama.2018.10136 · Cited by 471 · cited 1×
“…public workshops and guidances [53], and disease-specific guidances, such as in amyotrophic lateral sclerosis, where DHT were included for identifying and monitoring patients clinical trials is advancing rapidly, with innovative regulatory science frameworks being communicated broadly [55].”
BackgroundPratap, A., Neto, E. C., Snyder, P., Stepnowsky, C., Elhadad, N., Grant, D., Mohebbi, M. H., Mooney, S., Suver, C., Wilbanks, J., et al. (2020) · npj Digital Medicine · doi:10.1038/s41746-020-0224-8 · Cited by 410
Developing and adopting safe and effective digital biomarkers to improve patient outcomes
Coravos, A., Khozin, S., & Mandl, K. D. (2019) · npj Digital Medicine · doi:10.1038/s41746-019-0090-4 · Cited by 361
Lipsmeier, F., Taylor, K. I., Kilchenmann, T., Wolf, D., Scotland, A., Schjodt‐Eriksen, J., Cheng, W., Fernandez‐Garcia, I., Siebourg‐Polster, J., Jin, L., et al. (2018) · Movement Disorders · doi:10.1002/mds.27376 · Cited by 266
Self-citationThe Coronavirus Disease 2019 Crisis as Catalyst for Telemedicine for Chronic Neurological Disorders
Bloem, B. R., Dorsey, E. R., & Okun, M. S. (2020) · JAMA Neurology · doi:10.1001/jamaneurol.2020.1452 · Cited by 224 · cited 1×
“In the climate of the COVID-19 crisis, there will be a growing acceptance for the use of highly capable commercial devices demonstrated to be fit for purpose for an intended application [20].”
BackgroundSelf-citationStephenson, D., Hill, D., Cedarbaum, J. M., Tome, M., Vamvakas, S., Romero, K., Conrado, D. J., Dexter, D. T., Seibyl, J., Jennings, D., et al. (2019) · Journal of Parkinson’s Disease · doi:10.3233/jpd-191648 · Cited by 46
Self-citation
Cited by
Roussos, G., Herrero, T. R., Hill, D. L., Dowling, A. V., L. T. M. Müller, M., Evers, L. J. W., Burton, J., Derungs, A., Fisher, K., Kilambi, K. P., et al. (2022) · npj Digital Medicine · doi:10.1038/s41746-022-00643-4 · Cited by 28
Self-citationAccelerating Parkinson’s Disease drug development with federated learning approaches
Khanna, A., Adams, J., Antoniades, C., Bloem, B. R., Carroll, C., Cedarbaum, J., Cosman, J., Dexter, D. T., Dockendorf, M. F., Edgerton, J., et al. (2024) · npj Parkinson's Disease · doi:10.1038/s41531-024-00837-5 · Cited by 21
“…progress toward this goal, a number of PD cohorts have established multi-modal datasets derived from traditional and digital measures including the Oxford Parkinson ’ s Disease Centre (OPDC), MJFF, PPMI 50 – 52 , the Personalized Parkinson ’ s Project (PPP) 53 , and the CPP global consortium 17 .”
Self-citationIzmailova, E. S., Maguire, R. P., McCarthy, T. J., Müller, M. L. T. M., Murphy, P., & Stephenson, D. (2023) · Clinical and Translational Science · doi:10.1111/cts.13461 · Cited by 17
Self-citation
Metadata
- Authors
- Stephenson, D., Alexander, R., Aggarwal, V., Badawy, R., Bain, L., Bhatnagar, R., Bloem, B. R., Boroojerdi, B., Burton, J., Cedarbaum, J. M., Cosman, J., Dexter, D. T., Dockendorf, M., Dorsey, E. R., Dowling, A. V., Evers, L. J. W., Fisher, K., Frasier, M., Garcia-Gancedo, L., Goldsack, J. C., Hill, D., Hitchcock, J., Hu, M. T., Lawton, M. P., Lee, S. J., Lindemann, M., Marek, K., Mehrotra, N., Meinders, M. J., Minchik, M., Oliva, L., Romero, K., Roussos, G., Rubens, R., Sadar, S., Scheeren, J., Sengoku, E., Simuni, T., Stebbins, G., Taylor, K. I., Yang, B., Zach, N., & on behalf of the Critical Path for Parkinson’s Consortium
- Venue
- Digital Biomarkers
- Publisher
- S. Karger AG
- Published
- 2020-11-26
- Volume
- 4
- Issue
- Suppl. 1
- Pages
- 28-49
- ISSN
- 2504-110X (ISSN-L)
- OpenAlex
- W3109533980
- Cited by
- 63
- References
- 12
- FWCI
- 10.31
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Precompetitive Consensus Building to Facilitate the Use of Digital Health Technologies to Support Parkinson Disease Drug Development through Regulatory Science. https://app.cochat.ai/papers/10.1159/000512500
- The paper
- Stephenson, D., Alexander, R., Aggarwal, V., Badawy, R., Bain, L., Bhatnagar, R., Bloem, B. R., Boroojerdi, B., Burton, J., Cedarbaum, J. M., Cosman, J., Dexter, D. T., Dockendorf, M., Dorsey, E. R., Dowling, A. V., Evers, L. J. W., Fisher, K., Frasier, M., Garcia-Gancedo, L., . . . on behalf of the Critical Path for Parkinson’s Consortium. (2020). Precompetitive Consensus Building to Facilitate the Use of Digital Health Technologies to Support Parkinson Disease Drug Development through Regulatory Science. Digital Biomarkers. https://doi.org/10.1159/000512500
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.